Navigation Links
Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
Date:9/17/2007

ANN ARBOR, Mich., Sept. 17 /PRNewswire/ -- Terumo Heart, Inc. announced today that it had a successful European Launch Symposium at the European Association of Cardio-Thoracic Surgeons (EACTS) meeting in Geneva, Switzerland.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20070227/CLTU043LOGO )

A summary of the European Clinical Trial results for the DuraHeart(TM) Left Ventricular Assist System (LVAS) was presented by Dr. Aly El-Banayosy from the Heart Center Nordrhein-Westfalen in Bad Oeynhausen, Germany, followed by the presentation "The Emerging New Era of Mechanical Circulatory Support," by Dr. Eric Rose of Columbia University Medical Center in New York.

The symposium highlighted the DuraHeart device, as well as the BioValsalva Aortic Valved Conduit developed by Vascutek Ltd, a Terumo Company.

A summary of DuraHeart LVAS clinical results to-date (as of September 15, 2007):

* Patients enrolled = 33

* Median age (years) = 57 (29-73)

* Mean support duration (days) = 231194 (range: 17-803)

* Cumulative support duration = 7610 days (> 20 years)

* 7 patients (21%) supported > 1 year, and one supported > 2 years.

* 12 patients (36%) remain on support with a mean duration > 1 year (375

196 days)

* Kaplan Meier survival at 1 and 2 years was: 77% (all patients), 80% (<65

yrs), 90% (<60 yrs) and 100% (<50)

Chisato Nojiri, M.D., Ph.D., Chief Executive Officer for Terumo Heart, Inc., said; "We have had a number of significant milestones this year, most importantly receiving the CE Mark and a successful commercial launch in Europe."

The interest from surgeons at the EACTS has been extremely good. Dr. Nojiri commented, "We have been very pleased with the amount of interest from surgeons, both at this meeting and since receipt of the CE Mark. We are focusing significant resources on commercial activities in Europe and are looking forward to a U.S. clinical trial later this year."

The DuraHeart LVAS is a third generation circulatory support device intended to provide cardiac support for patients who are at risk of death due to end-stage left ventricular failure. It is currently the only approved implantable LVAS combining a centrifugal pump with magnetic levitation of the impeller, providing exceptional reliability and minimizing the potential for blood damage and thrombus. DuraHeart is not available in the United States.

Vascutek Deutschland GmbH, a Terumo Company, distributes DuraHeart through its Terumo Heart Division based in Hamburg, Germany. Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients. Terumo Corporation, located in Tokyo, Japan, is a leading

developer, manufacturer and global marketer of a wide array of medical products.


'/>"/>
SOURCE Terumo Heart, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
6. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
7. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
8. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/6/2017)... Texas , May 5, 2017   Provista , ... with more than 200,000 customers, today announced Jim Cunniff ... a wealth of executive and business experience to Provista, including ... compounding pharmacy in California . He assumed ... "Jim is a great fit for Provista," says ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® or ... a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance of ... Dr. Bedich offers a variety of cosmetic dentistry services at his practice that are ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... reproductive tract in which the endometrial lining of the uterus spreads into ... pain. Patients experiencing painful intercourse, painful periods, pelvic pain, or irregular bleeding ...
(Date:5/24/2017)... NY (PRWEB) , ... May 24, 2017 , ... ... the practice is offering holistic pediatric dentistry options for its patients on Long ... of the patient’s entire physical well being, and is one of the biggest ...
(Date:5/24/2017)... ... 2017 , ... Technique, technique, technique – with a dash of common sense. ... training and exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional pain ... Chang says. “Improper technique in lifting anything heavy or an attempt to lift too ...
(Date:5/23/2017)... ... May 23, 2017 , ... Allegheny Health Network ... The Alexis Joy D’Achille Center for Women’s Behavioral Health at West Penn Hospital ... western Pennsylvania for women suffering from pregnancy-related depression. Construction of the Center is ...
Breaking Medicine News(10 mins):